MLTX
MLTX clinical trials: MoonLake Immunotherapeutics
Every trial on ClinicalTrials.gov where MoonLake Immunotherapeutics is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
MLTX on the catalyst calendar · MLTX registry changes
- Primary completion Feb 4, 2028Sponsor estimatePhase 3NCT07223138A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisMoonLake Immunotherapeutics AG · Arthritis, PsoriaticEnrolling by invitationMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 4, 2027Sponsor estimatePhase 3NCT06641089Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseMoonLake Immunotherapeutics AG · Arthritis, PsoriaticActive, not recruitingMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2026ActualPhase 3NCT06641076Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugMoonLake Immunotherapeutics AG · Arthritis, PsoriaticActive, not recruitingMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2026ActualPhase 3NCT06768671An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to...MoonLake Immunotherapeutics AG · Hidradenitis SuppurativaCompletedMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2023ActualPhase 2NCT05640245Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisMoonLake Immunotherapeutics AG · Arthritis, PsoriaticCompletedMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2023ActualPhase 2NCT05322473Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaMoonLake Immunotherapeutics AG · Hidradenitis SuppurativaCompletedMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2025ActualPhase 3NCT06411899A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to...MoonLake Immunotherapeutics AG · Hidradenitis SuppurativaCompletedMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 13, 2028Sponsor estimatePhase 3NCT07007637A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe...MoonLake Immunotherapeutics AG · Hidradenitis SuppurativaEnrolling by invitationMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2025ActualPhase 3NCT06411379Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to...MoonLake Immunotherapeutics AG · Hidradenitis SuppurativaCompletedMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2025ActualPhase 1NCT06994936An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a...MoonLake Immunotherapeutics AG · Relative BioequivalenceCompletedMLTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner